AP505F
Goat Anti-Human Ig κ chain Antibody, FITC conjugate
Chemicon®, from goat
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
goat
Quality Level
conjugate
FITC conjugate
antibody form
affinity purified immunoglobulin
antibody product type
secondary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
shipped in
wet ice
target post-translational modification
unmodified
Related Categories
General description
Antibody molecules typically comprise two immunoglobulin light chains covalently bound to a pair of heavy chains. Immunoglobulin light chains occur in two types, designated by the Greek letters kappa and lambda. Kappa and lambda light chains are approximately 250 amino acids in length with an average mass of about 25 kDa. The ratio of kappa to lambda found in the immunoglobulin population varies by species.
Specificity
Reacts with human kappa light chains. Absorbed for human myeloma proteins with λ light chains.
Application
Immunofluorescence: ≤1 μg/106 cells.
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
This Goat anti-Human Ig κ chain Antibody, FITC conjugate is validated for use in IF for the detection of Human Ig κ chain.
Physical form
Purified by affinity chromatography on pooled human Igs with kappa light chains covalently linked to agarose. Liquid in 1.0 mL PBS/NaN3.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joel G Turner et al.
Oncotarget, 7(48), 78896-78909 (2016-11-03)
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service